These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 28272224)
41. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients. Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628 [TBL] [Abstract][Full Text] [Related]
42. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Alvarez T; Miller E; Duska L; Oliva E Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825 [TBL] [Abstract][Full Text] [Related]
43. Androgen Receptor Immunohistochemical Expression in Undifferentiated/Dedifferentiated Endometrial Carcinoma. Cao J; Hacking S; Chavarria-Bernal HD; Bhuiya TA; Khutti S Int J Gynecol Pathol; 2022 Jan; 41(1):28-34. PubMed ID: 33399351 [TBL] [Abstract][Full Text] [Related]
44. Differential expression of fascin, E-cadherin and vimentin: Proteins associated with survival of cholangiocarcinoma patients. Mao X; Chen D; Wu J; Li J; Zhou H; Wu Y; Duan X Am J Med Sci; 2013 Oct; 346(4):261-8. PubMed ID: 23221510 [TBL] [Abstract][Full Text] [Related]
45. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Silva EG; Deavers MT; Bodurka DC; Malpica A Int J Gynecol Pathol; 2006 Jan; 25(1):52-8. PubMed ID: 16306785 [TBL] [Abstract][Full Text] [Related]
46. Comparison of E-cadherin with STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different ER-alpha immunoprofile. Sulkowska U; Wincewicz A; Kanczuga-Koda L; Koda M; Sulkowski S Gynecol Endocrinol; 2018 Feb; 34(2):171-174. PubMed ID: 28937296 [TBL] [Abstract][Full Text] [Related]
47. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications. Hacking S; Jin C; Komforti M; Liang S; Nasim M Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229 [TBL] [Abstract][Full Text] [Related]
48. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771 [TBL] [Abstract][Full Text] [Related]
49. Significance of p53 expression in background endometrium in endometrial carcinoma. Nguyen TT; Hachisuga T; Urabe R; Kurita T; Kagami S; Kawagoe T; Shimajiri S; Nabeshima K Virchows Arch; 2015 Jun; 466(6):695-702. PubMed ID: 25788166 [TBL] [Abstract][Full Text] [Related]
50. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer. González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154 [TBL] [Abstract][Full Text] [Related]
51. [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Xue LY; Zou SM; Zheng S; Xie YQ; Wen P; Liu XY; Lin DM; Lü N Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):838-44. PubMed ID: 21223690 [TBL] [Abstract][Full Text] [Related]
52. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium. Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900 [TBL] [Abstract][Full Text] [Related]
54. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Strehl JD; Wachter DL; Fiedler J; Heimerl E; Beckmann MW; Hartmann A; Agaimy A Ann Diagn Pathol; 2015 Aug; 19(4):198-202. PubMed ID: 25920939 [TBL] [Abstract][Full Text] [Related]
55. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Scholten AN; Aliredjo R; Creutzberg CL; Smit VT Int J Gynecol Cancer; 2006; 16(3):1379-85. PubMed ID: 16803534 [TBL] [Abstract][Full Text] [Related]
56. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. Zhang ZM; Xiao S; Sun GY; Liu YP; Zhang FH; Yang HF; Li J; Qiu HB; Liu Y; Zhang C; Kang S; Shan BE Int J Gynecol Cancer; 2014 Mar; 24(3):534-40. PubMed ID: 24557437 [TBL] [Abstract][Full Text] [Related]
57. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Fadare O; Desouki MM; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Parkash V; Hecht JL Am J Surg Pathol; 2014 Feb; 38(2):189-96. PubMed ID: 24145649 [TBL] [Abstract][Full Text] [Related]
58. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Lax SF; Pizer ES; Ronnett BM; Kurman RJ Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673 [TBL] [Abstract][Full Text] [Related]
59. Aberrant expression of hypoxia-inducible factor 1α, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma. Feng Z; Gan H; Cai Z; Li N; Yang Z; Lu G; Chen J Jpn J Clin Oncol; 2013 Apr; 43(4):396-403. PubMed ID: 23372184 [TBL] [Abstract][Full Text] [Related]
60. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]